PRESS RELEASES

2020

September 22, 2020 - VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2020 - VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 - VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer
September 8, 2020 - VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
August 13, 2020 - VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020 - VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS – the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
August 3, 2020 - VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
June 22, 2020 - VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
June 4, 2020 - VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
June 1, 2020 - VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
May 31, 2020 - Annual General Meeting of shareholders of Vascular Biogenics Ltd. to be held at 16:00 (Israel time) on July 29, 2020, at our offices at 8 Hasatat St. Modiin, Israel. For further details please visit our Upcoming Events page
May 18, 2020 - VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
May 14, 2020 - VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 - VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq Rules
May 12, 2020 - VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules
May 7, 2020 - VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 6, 2020 - VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW
May 4, 2020 - VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14
May 4, 2020 - VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation
April 21, 2020 - VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111
April 6, 2020 - VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use
April 2, 2020 - Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier
March 26, 2020 - VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
March 19, 2020 - VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update
March 3, 2020 - VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19
February 20, 2020 - VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
January 8, 2020 - VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study